About Arix Bioscience
Arix Bioscience is a venture capital firm founded in 2016. It is primarily based out of London, United Kingdom. As of May 2023, Arix Bioscience has invested in 26 companies. It primarily invests in Series B round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and HealthTech. Most recently it participated in the $***** Series B round of Ensoma Overall, Arix Bioscience portfolio has seen 10 IPOs and 6 acquisitions including key companies like Pyxis Oncology, Evommune and Enliven Therapeutics. A lot of funds co-invest with Arix Bioscience, with names like Orbimed sharing a substantial percentage of its portfolio. Arix Bioscience has team of 6 people including 2 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series A, Series B & 4 more
Portfolio IPOs
Portfolio Acquisitions
Arix Bioscience's List of Top Investments
Arix Bioscience has a portfolio of 26 companies. Their most notable investments are in Sorriso Pharmaceuticals and Pyxis Oncology.Their portfolio spans across United States, United Kingdom, Denmark and 5 more locations. They have invested in Life Sciences, High Tech, HealthTech, across Series A, Series B and 4 more. Here is the list of top investments by Arix Bioscience:
Developer of antibody therapeutics for treating cancer. The product pipeline includes PYX-201 that targets fibronectin, PYX-202 that targets tumor antigen, and PYX-203 for hematological cancer. The antibody is used for initiating the immune response in dysfunctional immune cells in the tumor microenvironment to treat cancer such as tumor antigen-specific tumor-infiltrating lymphocytes (TILs).
Key facts about Pyxis Oncology
- Founded Year: 2019
- Location: Boston (United States)
- Stage: Public
- Total Funding till date: $194M
- Employee Count: 68 as on Jul 31, 2026
- Investors: RTW Investments, BVF Partners and 23 Others
- Latest Funding Round: Post IPO, Feb 27, 2024, $*****
- Highlight: Public
2. Evommune
Developer of therapeutic options for chronic inflammatory disorders. The pipeline drug candidates include v for rosacea, and atopic dermatitis, RORγt for psoriasis, MRGPRX2 for pruritus, and PKCϴ for atopic dermatitis. The company uses a tissue-based screening platform that helps in the drug development of inflammatory diseases.
Key facts about Evommune
- Founded Year: 2020
- Location: Sacramento (United States)
- Annual Revenue: $10M - $50M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $276M
- Employee Count: 67 as on Jul 31, 2026
- Investors: RTW Investments, Marshall Wace and 18 Others
- Latest Funding Round: Post IPO, Feb 12, 2026, $*****
- Highlight: Public
Developer of drugs for solid tumors and blood cancers. It offers precision oncology therapeutics which include ELVN-001, a small molecule kinase inhibitor that target the BCR-ABL gene fusion, andELVN-002 a HER2 inhibitor with activity against various HER2 mutations for non-small cell lung cancer and solid tumors.
Key facts about Enliven Therapeutics
- Founded Year: 2019
- Location: Boulder (United States)
- Stage: Public
- Total Funding till date: $140M
- Employee Count: 82 as on Jul 31, 2026
- Investors: Venrock, Lundbeck Foundation and 15 Others
- Latest Funding Round: Post IPO, Mar 21, 2024, $*****
- Highlight: Public
4. Autolus
Clinical-stage biopharmaceutical provider developing CAR T therapies for cancer and autoimmune diseases. It leverages advanced immune cell engineering, chimeric antigen receptor (CAR) technology, and proprietary T cell programming platforms to create precise, controlled, and highly active therapeutic products designed to improve patient outcomes. Its technology platform combines innovative cell programming capabilities with proprietary viral vector systems and semi-automated manufacturing processes to engineer patient-derived T cells capable of recognizing and eliminating disease-causing cells.
Key facts about Autolus
- Founded Year: 2015
- Location: London (United Kingdom)
- Annual Revenue: $1M - $10M as on Sep 30, 2016
- Stage: Public
- Total Funding till date: $181M
- Employee Count: 732 as on Jul 31, 2026
- Investors: Nextech Invest, 4Bio Capital and 7 Others
- Latest Funding Round: Post IPO, Feb 08, 2024, $*****
- Highlight: Public
Developer of drugs for the treatment of respiratory diseases. Its drug pipeline includes RPL-554 (Phase 2) for chronic obstructive pulmonary disease (COPD), cystic fibrosis, and asthma; VRP700 for cough which is available for out-licensing. It has also identified certain marine organisms, such as starfish, a natural source of novel anti-inflammatory polysaccharides (NAIPS) without anti-coagulant actions.
Key facts about Verona Pharma
- Founded Year: 2005
- Location: London (United Kingdom)
- Annual Revenue: $10M - $50M as on Dec 31, 2024
- Stage: Acquired
- Total Funding till date: $74.8M
- Employee Count: 149 as on Jul 31, 2026
- Investors: Access Industries, Foresite Capital and 20 Others
- Latest Funding Round: Post IPO, Jul 17, 2020, $*****
- Highlight: Acquired
Arix Bioscience's Year-on-Year Investment Trends
Arix Bioscience has invested in 26 companies over the last 10 years, with an average of 2 new investments annually in the last 10 years. Its most recent first time investment was in Evommune and most recent follow-on round was in Ensoma.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 0 | 0 | 0 |
2025 | 0 | 0 | 0 |
2024 | 0 | 0 | 0 |
2023 | 2 | 2 | 4 |
2022 | 0 | 0 | 0 |
2021 | 3 | 3 | 6 |
2020 | 2 | 2 | 4 |
2019 | 2 | 1 | 3 |
2018 | 5 | 2 | 7 |
2017 | 6 | 0 | 6 |
Arix Bioscience's Investments by Stage
Arix Bioscience has made 8 investments in Series A stage with an average round size of $33.1M, 8 investments in Series B stage with an average round size of $79.5M and 3 investments in Series C stage with an average round size of $71.2M.Stage of entry | No. of Investments |
|---|---|
Series A | 8 |
Series B | 8 |
Series C | 3 |
Post IPO | 2 |
Seed | 1 |
Others | 1 |
Note: We have considered here, only first round of investments
Arix Bioscience's Investments by Sector
Arix Bioscience has a diverse portfolio, with companies operating in the Life Sciences, High Tech, Sustainability Tech and HealthTech. Notably, it has invested in 24 Tech companies, 22 Enterprise (B2B) companies, 1 Social impact company and 1 company focusing on Software.Sector | No. of Investments |
|---|---|
Life Sciences | 23 |
High Tech | 5 |
Sustainability Tech | 2 |
HealthTech | 1 |
Note: We have considered here, only first round of investments
Arix Bioscience's Investments by Geography
Arix Bioscience has made most investments in United States (14), followed by France where it has made 2 investments.Country | No. of Investments |
|---|---|
United States | 14 |
France | 2 |
Israel | 2 |
United Kingdom | 2 |
Australia | 1 |
Others | 3 |
Note: We have considered here, only first round of investments
Arix Bioscience's recent investments
Arix Bioscience has not made any investment in 2026 so far.Here are the most recent investments by Arix Bioscience:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
May 16, 2023 | United States | Series B | 1225 | [+15] | |
Mar 28, 2023 | United States | Post IPO | 5573 | [+3] | |
Mar 28, 2023 | United States | Series B | 3945 | [+4] | |
Jan 05, 2023 | United States | Series B | 6939 | [+12] | |
Dec 22, 2021 | United States | Series A | 6398 |
IPOs and Publicly Listed companies in Arix Bioscience's Portfolio
10 of Arix Bioscience's portfolio companies have become public. Evommune got listed on the New York Stock Exchange (NYSE), in Nov 2025 at marketcap of $481M and Disc Medicine got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ).Here are Arix Bioscience's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Nov 06, 2025 | Mar 28, 2023 | Series B | 8106 | |
Dec 29, 2022 | Sep 02, 2021 | Series B | 7756 | |
Oct 29, 2021 | Dec 13, 2018 | Series C | 4072 | |
Oct 01, 2021 | Mar 05, 2021 | Series B | 9552 | |
Mar 12, 2020 | Mar 18, 2019 | Series B | 2168 |
Acquired companies in Arix Bioscience's Portfolio
6 companies from Arix Bioscience's portfolio have been acquired. The most recent acquisition was Verona Pharma in Jul 2025 by Merck for $*****.Here are Arix Bioscience's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Jul 09, 2025 | - | - | 4067 | |
Jan 08, 2024 | Jun 06, 2017 | Series B | 5015 | |
Jan 05, 2023 | - | - | 8752 | |
Oct 03, 2022 | Jul 05, 2017 | Series B | 6364 | |
Apr 28, 2021 | Jan 09, 2020 | Series C | 2462 |
Team profile of Arix Bioscience
Arix Bioscience has a team of 6 members including 2 Partners located in United States. Arix Bioscience's team does not sit on the board of any company as of now.Co-investors of Arix Bioscience
Over the past 10 years, 209 investors have co-invested in Arix Bioscience's portfolio companies. This includes funds and angels.
- Invested before Arix Bioscience: Alexandria, Orbimed and 52 others have invested in rounds before Arix Bioscience. There are 3 companies where Alexandria has invested before Arix Bioscience and 2 companies where Orbimed has invested before Arix Bioscience.
- Top Co-investors of Arix Bioscience: 74 investors entered a company along with Arix Bioscience. These include investors like Orbimed (3 companies).
- Invested after Arix Bioscience: A total of 81 investors have invested in Arix Bioscience's portfolio after their investments. Top Investors include RA Capital Management (5 companies), Citadel (3 companies) and Deep Track Capital (2 companies).
Recent News related to Arix Bioscience
•
RTW Biotech’s Acquisition of Arix Bioscience AssetsGlobal Legal Chronicle•Mar 20, 2024•Herbert Smith Freehills, RTW Investments, Arix Bioscience
•
RTW Biotech Opportunities NAV increases 2.5% in JanuaryMorningstar•Feb 15, 2024•RTW Investments, Arix Bioscience
•
RTW Biotech completes Arix investment in takeover run-upShareprices•Jan 22, 2024•RTW Investments, Arix Bioscience
•
•
•
Arix Bioscience Eyes $19 Million Return From Harpoon SaleAJ Bell•Jan 19, 2024•Arix Bioscience, Harpoon Therapeutics
•
Merck to Acquire Harpoon Therapeutics, Further Diversifying Oncology PipelineBusiness Wire•Jan 08, 2024•Merck, Harpoon Therapeutics, Merck Sharp & Dohme, Arix Bioscience and 3 others
•
•
Basilea Acquires Broad Spectrum Antifungal FosmanogepixContract Pharma•Nov 13, 2023•Basilea, Arix Bioscience, Lenz & Staehelin
•
RTW Biotech Opportunities to acquire Arix BioscienceQuoteddata•Nov 01, 2023•Arix Bioscience, RTW Investments
